Michelle Brown

Company: Moderna

Job title: Vice President, Portfolio Development, Oncology

Seminars:

Accelerating V940: A Strategic Blueprint for Translational to Late-Stage Clinical Development of Personalized Cancer Vaccines 11:00 am

• Integrating tumor profiling, neoantigen prediction, and manufacturing timelines to enable rapid patient-specific vaccine deployment • Designing robust clinical trials to inform pivotal strategy: from patient selection to combination approachesRead more

day: Conference Day Two

What It Takes to Hit the 30-Day Turnaround: Optimizing the Manufacturing Workflow for mRNA Based PCVs to Deliver Rapid & Regulator-Ready Batches 11:00 am

• Streamlining mRNA manufacturing workflows to reduce IVT, LNP, Purification cycle time, and manual intervention • Optimizing Phase II manufacturing operations to support a smooth transition to latestage readiness with improved repeatability, regulatory alignment, and trial scalability • Operationalizing real-time analytics, digital batch release, and platform-based regulatory strategies across end-to-end manufacturingRead more

day: Pre-Conference Manufacturing Focus Day

Expanding the Neoantigen Strategy Beyond Melanoma: Evolving Target Selection Across Tumor Types to Expand PCV Applicability 11:30 am

• Translating lessons from V940 to inform indication expansion and optimize antigen design across tumor types with differing immune responsiveness • Validating evolving antigen strategies in early-stage settings to accelerate clinical translation and enable faster access • Navigating regulatory considerations to determine when antigen selection strategy constitutes a new product vs an extension of platform…Read more

day: Conference Day One